{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T16:25:10Z","timestamp":1783700710035,"version":"3.55.0"},"reference-count":93,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100022011","name":"Cancer Research UK Cambridge Institute, University of Cambridge","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022011","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000771","name":"Prostate Cancer UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000771","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000892","name":"Prostate Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000892","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaloncologyonline.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Oncology"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.clon.2025.103804","type":"journal-article","created":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T04:04:59Z","timestamp":1742357099000},"page":"103804","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Expanding PARP Inhibitor Use in Prostate Cancer Beyond DNA Repair Defects"],"prefix":"10.1016","volume":"44","author":[{"given":"A.F.","family":"Palma dos Reis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8467-2581","authenticated-orcid":false,"given":"L.G.","family":"Faulkner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.W.","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2874-6894","authenticated-orcid":false,"given":"H.","family":"Dev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Pacey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.clon.2025.103804_bib1","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"41","key":"10.1016\/j.clon.2025.103804_bib2","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.15585\/mmwr.mm6941a1","article-title":"Prostate Cancer Incidence and Survival, by Stage and Race\/Ethnicity \u2014 United States, 2001\u20132017","volume":"69","author":"Siegel","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"11","key":"10.1016\/j.clon.2025.103804_bib3","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1038\/s43018-020-00141-0","article-title":"Accelerating precision medicine in metastatic prostate cancer","volume":"1","author":"Mateo","year":"2020","journal-title":"Nat Cancer"},{"key":"10.1016\/j.clon.2025.103804_bib4","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.12688\/f1000research.14499.1","article-title":"Recent advances in prostate cancer research: large-scale genomic analyses reveal novel driver mutations and DNA repair defects","volume":"7","author":"Frank","year":"2018","journal-title":"F1000Research"},{"issue":"7484","key":"10.1016\/j.clon.2025.103804_bib5","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nature12912","article-title":"Discovery and saturation analysis of cancer genes across 21 tumour types","volume":"505","author":"Lawrence","year":"2014","journal-title":"Nature"},{"issue":"7463","key":"10.1016\/j.clon.2025.103804_bib6","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.clon.2025.103804_bib7","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41391-019-0153-2","article-title":"Role of the DNA damage response in prostate cancer formation, progression and treatment","volume":"23","author":"Zhang","year":"2020","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"1","key":"10.1016\/j.clon.2025.103804_bib8","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41572-020-00243-0","volume":"7","author":"Rebello","year":"2021","journal-title":"Prostate Cancer Nat Rev Dis Primer"},{"issue":"5","key":"10.1016\/j.clon.2025.103804_bib9","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1056\/NEJMoa1603144","article-title":"Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer","volume":"375","author":"Pritchard","year":"2016","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.clon.2025.103804_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00029","article-title":"Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making","author":"Abida","year":"2017","journal-title":"JCO Precis Oncol"},{"issue":"6","key":"10.1016\/j.clon.2025.103804_bib11","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003998","article-title":"Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial","volume":"19","author":"Parker","year":"2022","journal-title":"PLOS Med"},{"issue":"7","key":"10.1016\/j.clon.2025.103804_bib12","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S1470-2045(18)30365-6","article-title":"Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"19","author":"Clarke","year":"2018","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.clon.2025.103804_bib13","doi-asserted-by":"crossref","first-page":"425","DOI":"10.2217\/fon-2021-0811","article-title":"Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: TALAPRO-2 phase III study design","volume":"18","author":"Agarwal","year":"2022","journal-title":"Future Oncol"},{"issue":"1","key":"10.1016\/j.clon.2025.103804_bib14","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.tibs.2023.11.001","article-title":"Causes and consequences of DNA single-strand breaks","volume":"49","author":"Caldecott","year":"2024","journal-title":"Trends Biochem Sci"},{"issue":"9","key":"10.1016\/j.clon.2025.103804_bib15","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/annonc\/mdz192","article-title":"A decade of clinical development of PARP inhibitors in perspective","volume":"30","author":"Mateo","year":"2019","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.clon.2025.103804_bib16","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1093\/annonc\/mdt384","article-title":"PARP Inhibitors for BRCA1\/2 mutation-associated and BRCA-like malignancies","volume":"25","author":"Lee","year":"2014","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.clon.2025.103804_bib17","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s11523-021-00796-4","article-title":"An Overview of PARP Inhibitors for the Treatment of Breast Cancer","volume":"16","author":"Cortesi","year":"2021","journal-title":"Target Oncol"},{"issue":"4","key":"10.1016\/j.clon.2025.103804_bib18","doi-asserted-by":"crossref","DOI":"10.1136\/ijgc-2022-004149","article-title":"Poly (ADP-ribose) polymerase inhibitors (PARPi) in ovarian cancer: lessons learned and future directions","volume":"33","author":"Caruso","year":"2023","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.clon.2025.103804_bib19","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1159557","article-title":"PARP inhibitors in metastatic prostate cancer","volume":"13","author":"Taylor","year":"2023","journal-title":"Front Oncol"},{"issue":"21","key":"10.1016\/j.clon.2025.103804_bib20","doi-asserted-by":"crossref","first-page":"5588","DOI":"10.1158\/0008-5472.CAN-12-2753","article-title":"Differential trapping of PARP1 and PARP2 by clinical PARP inhibitors","volume":"72","author":"Murai","year":"2012","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.clon.2025.103804_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.febslet.2010.11.024","article-title":"Synthetic lethality: General principles, utility and detection using genetic screens in human cells","volume":"585","author":"Nijman","year":"2011","journal-title":"FEBS Lett"},{"key":"10.1016\/j.clon.2025.103804_bib22","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2020.564601","article-title":"PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance","volume":"8","author":"Rose","year":"2020","journal-title":"Front Cell Dev Biol"},{"issue":"8007","key":"10.1016\/j.clon.2025.103804_bib23","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s41586-024-07217-2","article-title":"Transcription\u2013replication conflicts underlie sensitivity to PARP inhibitors","volume":"628","author":"Petropoulos","year":"2024","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.clon.2025.103804_bib24","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.ctrv.2010.03.003","article-title":"Pre-clinical and clinical evaluation of PARP inhibitors as tumour-specific radiosensitisers","volume":"36","author":"Powell","year":"2010","journal-title":"Cancer Treat Rev"},{"issue":"12","key":"10.1016\/j.clon.2025.103804_bib25","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/nrc3399","article-title":"DNA repair dysregulation from cancer driver to therapeutic target","volume":"12","author":"Curtin","year":"2012","journal-title":"Nat Rev Cancer"},{"issue":"11","key":"10.1016\/j.clon.2025.103804_bib26","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/s41568-021-00386-6","article-title":"Targeting the DNA damage response in immuno-oncology: developments and opportunities","volume":"21","author":"Chabanon","year":"2021","journal-title":"Nat Rev Cancer"},{"issue":"7970","key":"10.1016\/j.clon.2025.103804_bib27","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/s41586-023-06069-6","article-title":"The complementarity of DDR, nucleic acids and anti-tumour immunity","volume":"619","author":"Kornepati","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.clon.2025.103804_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114770","article-title":"Dual antitumor immunomodulatory effects of PARP inhibitor on the tumor microenvironment: A counterbalance between anti-tumor and pro-tumor","volume":"163","author":"Yi","year":"2023","journal-title":"Biomed Pharmacother"},{"issue":"32","key":"10.1016\/j.clon.2025.103804_bib31","doi-asserted-by":"crossref","first-page":"3763","DOI":"10.1200\/JCO.20.01035","article-title":"Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration","volume":"38","author":"Abida","year":"2020","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.clon.2025.103804_bib32","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1158\/1078-0432.CCR-20-0394","article-title":"Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study","volume":"26","author":"Abida","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.clon.2025.103804_bib33","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1056\/NEJMoa2214676","article-title":"Rucaparib or Physician\u2019s Choice in Metastatic Prostate Cancer","volume":"388","author":"Fizazi","year":"2023","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.clon.2025.103804_bib34","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1056\/NEJMoa1506859","article-title":"DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer","volume":"373","author":"Mateo","year":"2015","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.clon.2025.103804_bib35","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1470-2045(19)30684-9","article-title":"Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial","volume":"21","author":"Mateo","year":"2020","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.clon.2025.103804_bib36","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1158\/1078-0432.CCR-21-3940","article-title":"Tumor Genomic Testing for >4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib)","volume":"28","author":"Hussain","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clon.2025.103804_bib37","article-title":"PARP inhibitors for prostate cancer","author":"Longoria","year":"2023","journal-title":"Semin Oncol"},{"issue":"3","key":"10.1016\/j.clon.2025.103804_bib38","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/S1470-2045(21)00757-9","article-title":"Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial","volume":"23","author":"Smith","year":"2022","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.clon.2025.103804_bib39","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1186\/s12885-024-12388-2","article-title":"The efficacy and safety of PARP inhibitors in mCRPC with HRR mutation in second-line treatment: a systematic review and bayesian network meta-analysis","volume":"24","author":"Zhu","year":"2024","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/j.clon.2025.103804_bib40","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.clgc.2023.12.011","article-title":"PARP Inhibitors in Metastatic Prostate Cancer: A Comprehensive Systematic Review and Meta-analysis of Existing Evidence","volume":"22","author":"Ditonno","year":"2024","journal-title":"Clin Genitourin Cancer"},{"issue":"11","key":"10.1016\/j.clon.2025.103804_bib41","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1158\/2159-8290.CD-13-0108","article-title":"A Hormone\u2013DNA Repair Circuit Governs the Response to Genotoxic Insult","volume":"3","author":"Goodwin","year":"2013","journal-title":"Cancer Discov"},{"issue":"11","key":"10.1016\/j.clon.2025.103804_bib42","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1158\/2159-8290.CD-13-0172","article-title":"Androgen Receptor Signaling Regulates DNA Repair in Prostate Cancers","volume":"3","author":"Polkinghorn","year":"2013","journal-title":"Cancer Discov"},{"issue":"480","key":"10.1016\/j.clon.2025.103804_bib43","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aam7479","article-title":"Androgen receptor inhibitor\u2013induced \u201cBRCAness\u201d and PARP inhibition are synthetically lethal for castration-resistant prostate cancer","volume":"10","author":"Li","year":"2017","journal-title":"Sci Signal"},{"issue":"326","key":"10.1016\/j.clon.2025.103804_bib44","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.2005070","article-title":"Targeting Poly(ADP-Ribose) Polymerase and the c-Myb\u2013Regulated DNA Damage Response Pathway in Castration-Resistant Prostate Cancer","volume":"7","author":"Li","year":"2014","journal-title":"Sci Signal"},{"issue":"12","key":"10.1016\/j.clon.2025.103804_bib45","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1158\/2159-8290.CD-12-0120","article-title":"Dual Roles of PARP-1 Promote Cancer Growth and Progression","volume":"2","author":"Schiewer","year":"2012","journal-title":"Cancer Discov"},{"key":"10.1016\/j.clon.2025.103804_bib46","series-title":"Poly(ADP-Ribose) polymerase. Vol 2609. Methods in molecular biology","first-page":"329","article-title":"Examining the Effect of PARP-1 Inhibitors on Transcriptional Activity of Androgen Receptor in Prostate Cancer Cells","author":"Makhov","year":"2023"},{"issue":"12","key":"10.1016\/j.clon.2025.103804_bib47","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1158\/1541-7786.MCR-23-0358","article-title":"The Androgen Receptor Does Not Directly Regulate the Transcription of DNA Damage Response Genes","volume":"21","author":"Hasterok","year":"2023","journal-title":"Mol Cancer Res"},{"issue":"18","key":"10.1016\/j.clon.2025.103804_bib48","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1200\/JCO.22.01649","article-title":"Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer","volume":"41","author":"Chi","year":"2023","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.clon.2025.103804_bib49","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200043","article-title":"Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer","volume":"1","author":"Clarke","year":"2022","journal-title":"NEJM Evid"},{"issue":"10398","key":"10.1016\/j.clon.2025.103804_bib102","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0140-6736(23)01055-3","article-title":"Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial","volume":"402","author":"Agarwal","year":"2023","journal-title":"Lancet"},{"issue":"6_suppl","key":"10.1016\/j.clon.2025.103804_bib50","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.6_suppl.LBA16","article-title":"Final overall survival (OS) in PROpel: Abiraterone (abi) and olaparib (ola) versus abiraterone and placebo (pbo) as first-line (1L) therapy for metastatic castration-resistant prostate cancer (mCRPC)","volume":"41","author":"Clarke","year":"2023","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.clon.2025.103804_bib51","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.annonc.2023.06.009","article-title":"Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial","volume":"34","author":"Chi","year":"2023","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.clon.2025.103804_bib52","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1200\/JCO.2017.75.7310","article-title":"Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012","volume":"36","author":"Hussain","year":"2018","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clon.2025.103804_bib53","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3390\/ijms25010078","article-title":"Synthetic Lethality by Co-Inhibition of Androgen Receptor and Polyadenosine Diphosphate-Ribose in Metastatic Prostate Cancer","volume":"25","author":"Calabrese","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1016\/j.clon.2025.103804_bib54","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/bju.16130","article-title":"Poly(adenosine diphosphate-ribose) polymerase inhibitor combinations in first-line metastatic castrate-resistant prostate cancer setting: a systematic review and m eta-analysis","volume":"132","author":"Sayyid","year":"2023","journal-title":"BJU Int"},{"key":"10.1016\/j.clon.2025.103804_bib55","doi-asserted-by":"crossref","unstructured":"Messina C, Giunta EF, Signori A, Rebuzzi SE, Banna GL, Maniam A, et al. Combining PARP Inhibitors and Androgen Receptor Signalling Inhibitors in Metastatic Prostate Cancer: A Quantitative Synthesis and Meta-analysis. Eur Urol Oncol. Published online August 2023:S2588931123001554. doi:10.1016\/j.euo.2023.07.013.","DOI":"10.1016\/j.euo.2023.07.013"},{"key":"10.1016\/j.clon.2025.103804_bib68","unstructured":"National Institute for Health and Care Excellence. Olaparib with Abiraterone for Untreated Hormone-Relapsed Metastatic Prostate Cancer. https:\/\/www.nice.org.uk\/guidance\/ta951\/chapter\/1-Recommendations."},{"issue":"3","key":"10.1016\/j.clon.2025.103804_bib56","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.eururo.2023.03.038","article-title":"PARP Inhibitors for Prostate Cancer: Tangled up in PROfound and PROpel (and TALAPRO-2) Blues","volume":"84","author":"Beije","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.clon.2025.103804_bib57","article-title":"Use of PARP inhibitors in prostate cancer: from specific to broader application","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Endocrinol"},{"issue":"7713","key":"10.1016\/j.clon.2025.103804_bib58","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/s41586-018-0291-z","article-title":"CRISPR screens identify genomic ribonucleotides as a source of PARP-trapping lesions","volume":"559","author":"Zimmermann","year":"2018","journal-title":"Nature"},{"issue":"21","key":"10.1016\/j.clon.2025.103804_bib60","doi-asserted-by":"crossref","DOI":"10.1172\/JCI178278","article-title":"RNASEH2B loss and PARP inhibition in advanced prostate cancer","volume":"134","author":"Carmichael","year":"2024","journal-title":"J Clin Invest"},{"issue":"37","key":"10.1016\/j.clon.2025.103804_bib61","doi-asserted-by":"crossref","first-page":"4271","DOI":"10.1038\/s41388-022-02427-2","article-title":"A genome-wide CRISPR-Cas9 knockout screen identifies novel PARP inhibitor resistance genes in prostate cancer","volume":"41","author":"Ipsen","year":"2022","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.clon.2025.103804_bib62","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/s41467-023-35880-y","article-title":"CRISPR screens reveal genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancer","volume":"14","author":"Tsujino","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.clon.2025.103804_bib63","article-title":"3D CRISPR screen in prostate cancer cells reveals PARP inhibitor sensitization through TBL1XR1-SMC3 interaction","volume":"12","author":"Zhang","year":"2022","journal-title":"Front Oncol"},{"issue":"11","key":"10.1016\/j.clon.2025.103804_bib64","doi-asserted-by":"crossref","first-page":"5634","DOI":"10.1093\/nar\/gkz286","article-title":"A novel CRISPR-engineered prostate cancer cell line defines the AR-V transcriptome and identifies PARP inhibitor sensitivities","volume":"47","author":"Kounatidou","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.clon.2025.103804_bib65","unstructured":"Hussain MHA, Kocherginsky M, Agarwal N, Adra N, Zhang J, Paller CJ, et al. BRCAAWAY: a randomized phase 2 trial of abiraterone, olaparib, or abiraterone + olaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) with DNA repair defects."},{"issue":"2","key":"10.1016\/j.clon.2025.103804_bib73","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/onco.13585","article-title":"FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious BRCA-Mutated Metastatic Castrate-Resistant Prostate Cancer","volume":"26","author":"Anscher","year":"2021","journal-title":"The Oncologist"},{"key":"10.1016\/j.clon.2025.103804_bib74","unstructured":"National Institute of Health and Care Excellence (NICE). Prostate cancer (hormone relapsed, homologous recombination deficiency, metastatic) \u2013 rucaparib (after 1 therapy) [ID6127]. [GID-TA11219]."},{"issue":"21","key":"10.1016\/j.clon.2025.103804_bib75","doi-asserted-by":"crossref","first-page":"4724","DOI":"10.1158\/1078-0432.CCR-22-0301","article-title":"Preclinical characterization of AZD5305, a next generation, highly selective PARP1 inhibitor and trapper","volume":"28","author":"Illuzzi","year":"2022","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"4_suppl","key":"10.1016\/j.clon.2025.103804_bib76","article-title":"PETRANHA: Phase 1\/2 study of AZD5305 + novel hormonal agents in patients with metastatic prostate cancer\u2013Interim safety and pharmacokinetic results","volume":"42","author":"Arun","year":"2024","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.clon.2025.103804_bib77","doi-asserted-by":"crossref","first-page":"4520","DOI":"10.1007\/s12325-021-01823-6","article-title":"Real-World Treatment Patterns and Overall Survival of Patients with Metastatic Castration-Resistant Prostate Cancer in the US Prior to PARP Inhibitors","volume":"38","author":"Shore","year":"2021","journal-title":"Adv Ther"},{"issue":"4_suppl","key":"10.1016\/j.clon.2025.103804_bib78","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.4_suppl.TPS356","article-title":"ASCERTAIN: An open-label, randomized, phase 1, window-of-opportunity study to investigate the biological effects of AZD5305 and darolutamide alone or in combination in men with prostate cancer eligible for radical prostatectomy","volume":"42","author":"Pacey","year":"2024","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.clon.2025.103804_bib79","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1158\/2159-8290.CD-18-1218","article-title":"PARP Inhibitor Efficacy Depends on CD8+ T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer","volume":"9","author":"Pantelidou","year":"2019","journal-title":"Cancer Discov"},{"issue":"6","key":"10.1016\/j.clon.2025.103804_bib80","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1158\/2159-8290.CD-18-1218","article-title":"PARP Inhibitor Efficacy Depends on CD8+ T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer","volume":"9","author":"Pantelidou","year":"2019","journal-title":"Cancer Discov"},{"issue":"10","key":"10.1016\/j.clon.2025.103804_bib81","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.trecan.2021.05.004","article-title":"Development of poly(ADP-ribose) polymerase inhibitor and immunotherapy combinations: progress, pitfalls, and promises","volume":"7","author":"Pham","year":"2021","journal-title":"Trends Cancer"},{"issue":"6","key":"10.1016\/j.clon.2025.103804_bib82","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/s41416-023-02326-7","article-title":"PARP inhibitors: enhancing efficacy through rational combinations","volume":"129","author":"Bhamidipati","year":"2023","journal-title":"Br J Cancer"},{"issue":"16","key":"10.1016\/j.clon.2025.103804_bib83","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241612978","article-title":"Parp Inhibitors and Radiotherapy: A New Combination for Prostate Cancer (Systematic Review)","volume":"24","author":"Rivero Belench\u00f3n","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"10","key":"10.1016\/j.clon.2025.103804_bib84","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1097\/RLU.0000000000005390","article-title":"177Lu-PSMA With Olaparib Radiosensitization Potentiates Response and Toxicity in Extensive Castration-Resistant Metastatic Prostate cancer","volume":"49","author":"Kao","year":"2024","journal-title":"Clin Nucl Med"},{"issue":"12","key":"10.1016\/j.clon.2025.103804_bib85","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/j.annonc.2020.08.2102","article-title":"ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer","volume":"31","author":"Miller","year":"2020","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.clon.2025.103804_bib86","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1158\/1078-0432.CCR-20-0394","article-title":"Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study","volume":"26","author":"Abida","year":"2020","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"22","key":"10.1016\/j.clon.2025.103804_bib87","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for Metastatic Castration-Resistant Prostate Cancer","volume":"382","author":"De Bono","year":"2020","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.clon.2025.103804_bib88","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1038\/bjc.2012.451","article-title":"Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer","volume":"107","author":"Abkevich","year":"2012","journal-title":"Br J Cancer"},{"issue":"15","key":"10.1016\/j.clon.2025.103804_bib89","doi-asserted-by":"crossref","first-page":"3764","DOI":"10.1158\/1078-0432.CCR-15-2477","article-title":"Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer","volume":"22","author":"Telli","year":"2016","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"3","key":"10.1016\/j.clon.2025.103804_bib90","first-page":"280","article-title":"Establishing the homologous recombination score threshold in metastatic prostate cancer patients to predict the efficacy of PARP inhibitors","volume":"4","author":"Zhao","year":"2024","journal-title":"J Natl Cancer Cent"},{"issue":"16","key":"10.1016\/j.clon.2025.103804_bib91","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1158\/1078-0432.CCR-22-3156","article-title":"Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes","volume":"29","author":"Pikkusaari","year":"2023","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"12","key":"10.1016\/j.clon.2025.103804_bib92","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201809172","article-title":"A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation","volume":"10","author":"Castroviejo-Bermejo","year":"2018","journal-title":"EMBO Mol Med"},{"issue":"10","key":"10.1016\/j.clon.2025.103804_bib93","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.3390\/cancers12102805","article-title":"The RECAP Test Rapidly and Reliably Identifies Homologous Recombination-Deficient Ovarian Carcinomas","volume":"12","author":"Van Wijk","year":"2020","journal-title":"Cancers"},{"issue":"21","key":"10.1016\/j.clon.2025.103804_bib94","doi-asserted-by":"crossref","first-page":"6708","DOI":"10.1158\/1078-0432.CCR-17-0544","article-title":"Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer","volume":"23","author":"Weigelt","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.clon.2025.103804_bib95","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1158\/2159-8290.CD-17-0261","article-title":"Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition","volume":"7","author":"Goodall","year":"2017","journal-title":"Cancer Discov"},{"issue":"12","key":"10.1016\/j.clon.2025.103804_bib97","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/s41571-021-00532-x","article-title":"Understanding and overcoming resistance to PARP inhibitors in cancer therapy","volume":"18","author":"Dias","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.clon.2025.103804_bib96","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ejca.2019.11.012","article-title":"Circulating HOXA9-methylated tumour DNA: A novel biomarker of response to poly (ADP-ribose) polymerase inhibition in BRCA-mutated epithelial ovarian cancer","volume":"125","author":"Rusan","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clon.2025.103804_bib98","series-title":"Longitudinal profiling identifies co-occurring BRCA1\/2 reversions, TP53BP1, RIF1 and PAXIP1 mutations in PARP inhibitor resistant advanced breast cancer","author":"Harvey-Jones","year":"2024"},{"issue":"10","key":"10.1016\/j.clon.2025.103804_bib99","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.tcb.2019.07.008","article-title":"PARP Inhibitor Resistance: A Tug-of-War in BRCA-Mutated Cells","volume":"29","author":"Noordermeer","year":"2019","journal-title":"Trends Cell Biol"},{"issue":"9","key":"10.1016\/j.clon.2025.103804_bib100","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1158\/2159-8290.CD-17-0419","article-title":"Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma","volume":"7","author":"Kondrashova","year":"2017","journal-title":"Cancer Discov"},{"issue":"8","key":"10.1016\/j.clon.2025.103804_bib101","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/s41556-018-0140-1","article-title":"Shieldin complex promotes DNA end-joining and counters homologous recombination in BRCA1-null cells","volume":"20","author":"Dev","year":"2018","journal-title":"Nat Cell Biol"}],"container-title":["Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655525000597?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655525000597?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T08:36:40Z","timestamp":1762331800000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0936655525000597"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":93,"alternative-id":["S0936655525000597"],"URL":"https:\/\/doi.org\/10.1016\/j.clon.2025.103804","relation":{},"ISSN":["0936-6555"],"issn-type":[{"value":"0936-6555","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Expanding PARP Inhibitor Use in Prostate Cancer Beyond DNA Repair Defects","name":"articletitle","label":"Article Title"},{"value":"Clinical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clon.2025.103804","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Ltd on behalf of The Royal College of Radiologists.","name":"copyright","label":"Copyright"}],"article-number":"103804"}}